Skip to content

Study of 18F-PSMA-1007 PET/CT imaging in the detection of biochemical recurrence of prostate cancer

Study of 18F-PSMA-1007 PET/CT imaging in the detection of biochemical recurrence of prostate cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049853
Enrollment
Unknown
Registered
2021-08-10
Start date
2021-08-20
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Gold Standard:The metabolic activity of PSMA in prostate was significantly increased, and the postoperative pathological data or puncture pathological results.
Index test:PET/CT,Prostate&#32
antigen(PSMA)

Sponsors

General Hospital of Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=40 years old, male patients; 2. After radical prostatectomy, considering biochemical recurrence and seeking for biochemical recurrence; 3. Those without severe liver and kidney insufficiency; 4. Those who have no childbearing requirements in the past 3 months; 5. Those who agree to the imaging and sign the written informed consent form, are willing and able to follow up in time according to the requirements of the program.

Exclusion criteria

Exclusion criteria: 1. Patients with prostate cancer complicated with other malignant tumors; 2. Patients who are unable to cooperate with examination, cachexia or drug allergy.

Design outcomes

Primary

MeasureTime frame
Standard intake value;

Countries

China

Contacts

Public ContactLi Yanmei

General Hospital of Ningxia Medical University

amay5059@163.com+86 13895496683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026